Drugmakers have spent millions of dollars on ads and lobbying to attack proposals that would jeopardize their pricing power, according to The Wall Street Journal.
Pharmacy
Sandoz, the generic unit of Novartis, has expanded the recall of its heartburn medications containing ranitidine to the U.S., according to STAT.
Akcea Therapeutics, a Boston-based biotechnology company, has replaced three of its top executives.
Congress will hold a hearing Sept. 25 to discuss four proposed drug-pricing plans.
CVS Health, Walgreens and Walmart all have announced plans to invest more in face-to-face healthcare.
Advertisement
Ten hospitals and health systems posted job listings seeking pharmacy leaders in the last week.
Insulin has become so unaffordable that some patients dependent on it are turning to the black market, according to WGME.
Senior citizens are denied prescriptions millions of times each year at the pharmacy counter because the drugs are not covered by their Medicare plan, according to a report published Sept. 18 by the Office of the Inspector General.
India's Dr. Reddy's Laboratories is the latest drugmaker to stop distribution of ranitidine, the generic version of Zantac, after a potential cancer-causing impurity was found in the drug, according to Bloomberg.
Using drugs to treat conditions they are not FDA approved for, known as off-label use, is exacerbating the drug shortage problem, according to a Kaiser Health News article published by The Washington Post.